The Duke Preclinical Translational Research Unit is a developing CCSG Shared Resource which provides Duke or external investigators the opportunity to carry out critical in vivo experiments in a semi-independent laboratory, with input and oversight from experts in cancer biology, statistics, medical device, and animal experimentation, while having available all of the resources and expertise present at Duke. Our goal is to generate high quality, documented data, focusing on:
The Duke Preclinical Translational Research Unit Shared Resource has established SOPs for commonly used protocols among which are tumor inoculation, tumor growth delay, TCD50, metastasis assays, and toxicity testing. These services are undertaken by skilled technicians and the data is collected in accordance with the highest standards of GLP. To this end, the unit will keep records of all original data produced to assist the PIs in future analysis and investigations.
The facility will assist investigators with navigation of FDA regulations, IACUC regulations and compliance with IRB and clinical trials regulations. The services provided will ensure that data collected will be standardized and of the highest quality which will meet the requirements of publications and funding bodies.
This developing shared resource is a service oriented core which functions to ensure that these standards are met and provide significant value-added service to the PI by:
This will establish publication standards ensuring transparency of original data and methodology. This will also verifiably eliminate any suspicion of common problems such as inappropriate data exclusion or inappropriate statistical tests
LABCAT preclinical data management software (www.labcat.com) is used in this core. This is GLP compliant software that facilitates secure electronic medical record keeping for preclinical studies. Features include data collection, study management, data analysis and reporting system for pre-clinical investigations. Original study data is managed through this software which maintains data security and provenance from study design and setup, through data collection and analysis.
Pre-Clinical Translational Research Unit
Led by Greg Palmer, PhD, chief director, and Gabi Hanna, MD, executive director, the Duke Pre-clinical Translational Research Unit provides Duke Cancer Institute members the opportunity to perform critical in vivo experiments in a semi-independent laboratory, with input and oversight from experts in cancer biology, statistics, medical device and animal experimentation. More
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More